“…VSMCs derived from human iPSCs can also provide an unlimited cell source for autologous cell-based therapies and vascular disease models, as well as for studying pathophysiological mechanisms (Table 1). Differentiated iPSC-derived VSMCs express myogenic proteins such as ACTA2, TAGLN, MYH10, CALM1, CNN1, CALD1, myosin light chain genes, MYLK1, and late VSMCs differentiation marker MYH11, and demonstrate fibrillar organization and contractile responses to receptor-and non-receptor-mediated agonists characteristic of the development of VSMCs with the contractile phenotype (Bajpai et al, 2012;Biel et al, 2015;Patsch et al, 2015;Paik et al, 2018;Kwong et al, 2019;Duan et al, 2021;Islam et al, 2022). Cell surface markers such as PDGFRB (CD140b) and LRP1 (CD91) are present in both iPSC-derived progenitor and mature VSMCs (Biel et al, 2015).…”